Current standard treatment, including non-anthracycline-based chemotherapy and optimal combining of radiotherapy, has dramatically improved outcomes of patients with extranodal natural killer/T-cell lymphoma (ENKTL) during the last decade. This study was conducted to investigate the clinical outcome of ENKTL patients with relapsed or progressive disease after initial current standard therapy.

中文翻译：

---

超越一线非蒽环类化学疗法治疗结外NK / T细胞淋巴瘤：首次复发和疾病进展后患者的挽救性疗法的临床结果和当前观点

当前的标准治疗方法，包括基于非蒽环类的化学疗法和放疗的最佳组合，在过去十年中已显着改善了结外自然杀手/ T细胞淋巴瘤（ENKTL）患者的预后。这项研究的目的是调查目前标准治疗后ENKTL复发或进行性疾病患者的临床结局。